key: cord-0797075-cyavvqzl
authors: Greenstein, Yonatan Y.
title: Inaccurate conclusions by Tang and colleagues
date: 2020-05-26
journal: J Thromb Haemost
DOI: 10.1111/jth.14857
sha: f99613ebd25eee6fad31ba66ea33548ba8c41f71
doc_id: 797075
cord_uid: cyavvqzl

I read with interest the study by Tang and colleagues, published March 27, 2020, entitled "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease patients with coagulopathy." Unfortunately, this retrospective study came to conclusions that are inaccurate with the information provided. The authors use of the word "therapy" implies that patients were given therapeutic doses of anticoagulants, however, doses appear to be most consistent with prophylaxis dosing. The authors report that 94 patients received enoxaparin at 40-60mg/day. They did not specify the route of administration, subcutaneous (SC) or intravenous (IV), nor did they specify the percentage of patients that received which dose. The 40mg per day dose of enoxaparin given SC is the prophylactic dose. The 60mg per day IV dose would be therapeutic for patients weighing 40kg, not a typical weight for an adult patient.

I read with interest the study by Tang and colleagues, published March 27, 2020, entitled "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease patients with coagulopathy." Unfortunately, this retrospective study came to conclusions that are inaccurate with the information provided.

The authors use of the word "therapy" implies that patients were given therapeutic doses of anticoagulants; however, doses appear to be most consistent with prophylaxis dosing. The authors report that 94 patients received enoxaparin at 40 to 60 mg/day. They did not specify the route of administration, subcutaneous or intravenous, nor did they specify the percentage of patients that received which There is concern that patients with COVID-19 are at higher risk of developing VTE. I am aware of just one study to date that attempted to elucidate the prevalence of VTE. 3 The American Society of Hematology recommends against empiric therapeutic anticoagulation for COVID-19 patients given lack of evidence of benefit and potential harm. 4 As the world fights this pandemic, high-quality prospective studies are required to further elucidate the best way to manage the coagulopathy that we are seeing in patients critically ill with COVID-19. Hospitals will need to establish safe ways to aggressively test for the presence of VTE in these patients to inform therapeutic anticoagulation, focusing on minimizing exposure of health care workers to the virus.

None. 

A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia